FDA approves expanded label for NAMZARIC to treat moderate to severe Alzheimer’s disease

Allergan and Adamas Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved a new, expanded label for NAMZARIC (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI). http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda-approves-expanded-label-for-namzaric-to-treat-moderate-to-severe-alzheimers-disease-200716-4955079